Deciphering the Role of Nanoparticle-based Treatment for Parkinson's Disease

Curr Drug Metab. 2021;22(7):550-560. doi: 10.2174/1389200222666210202110129.

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder that exerts a huge burden on our society. The occurrence of this neurodegenerative disease has been increasing day-by-day. PD can be a serious concern if the patients are left untreated. However, conventional treatment has many side-effects and less bioavailability in the brain. Therefore, the necessary measurement is required to solve the limitations of PD treatment. Nanotechnology has made a major contribution to comprehend PD pathogenesis. Nanotechnology can provide efficient therapies that have reduced side-effects and increased bioavailability in the brain. This review emphasizes the emerging promise of nanoparticle-based treatment, drug delivery, and other therapeutic approaches for PD. Besides, the advantages of different approaches on nanotechnology platforms are far better over conventional therapy in the treatment of PD.

Keywords: Parkinson's disease; blood-brain barrier.; nanoparticles; nanotechnology; progressive neurodegenerative disorder; α-synuclein.

Publication types

  • Review

MeSH terms

  • Antiparkinson Agents / administration & dosage
  • Antiparkinson Agents / pharmacokinetics
  • Antiparkinson Agents / therapeutic use*
  • Biological Availability
  • Humans
  • Nanoparticle Drug Delivery System / administration & dosage
  • Nanoparticle Drug Delivery System / pharmacokinetics
  • Nanoparticle Drug Delivery System / therapeutic use*
  • Nanotechnology / methods
  • Parkinson Disease / drug therapy*

Substances

  • Antiparkinson Agents
  • Nanoparticle Drug Delivery System